The role of ecology in the region of residence of patients with epidermolysis bullosa and during the experiment
- Authors: Gadzhimuradov M.N.1, Gadzhimuradova M.M.1, Torshina I.E.2, Magomedov M.G.1, Alieva M.G.3
-
Affiliations:
- Dagestan State Medical Academy
- Smolensk State Medical University
- Republican Skin and Venereological Dispensary
- Issue: Vol 27, No 3 (2024)
- Pages: 324-339
- Section: DERMATOLOGY
- URL: https://journals.rcsi.science/1560-9588/article/view/262721
- DOI: https://doi.org/10.17816/dv623210
- ID: 262721
Cite item
Abstract
BACKGROUND: A person is constantly influenced by the environment, which determines his state of health. Animal testing is used to determine the danger of certain chemical agents of inanimate nature. To extrapolate the experimental result to humans, the body of patients with the dystrophic form of epidermolysis bullosa, which has a low threshold of resistance to aggressive stimuli, is preferable.
AIM: To study the impact of anthropogenic physicochemical factors on the skin of white mice, as well as environmental ecology on the population of patients with the dystrophic form of congenital epidermolysis bullosa.
MATERIALS AND METHODS: Scientific research is both observational and interventional. The observational part of the study included patients suffering from dystrophic form of epidermolysis bullosa. There are white mice in the interventional part.
RESULTS: Seeding with agrochemicals causes skin eczema, periorbital dermatitis, finger mutation and contracture, claw deformity and chronic itching in white mice. The possibility and criteria for extrapolating the results of the experiment to patients suffering from dystrophic form of epidermolysis bullosa have been established. These criteria include: itching of the skin, mutation and pseudosyndactyly of the fingers. The effect on the body of patients with dystrophic form of epidermolysis bullosa with toxic agents was carried out by the living environment. It has been established that in order to achieve the positive effect of complex therapy, in addition to highly qualified medical care, an environmentally safe living environment is necessary. Traveling and living in conditions that do not pose an environmental danger to humans helps to reduce the severity of the disease and improve their quality of life.
CONCLUSION: The ecology of the living environment determines the effectiveness of therapy in patients with dystrophic form of epidermolysis bullosa, as well as the timing of manifestation and severity of the disease. A healthy environment contributes to the epithelization of ulcerative elements and the disappearance of itching.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Marat N. Gadzhimuradov
Dagestan State Medical Academy
Author for correspondence.
Email: gabenu@mail.ru
ORCID iD: 0000-0002-3663-3235
SPIN-code: 9611-5619
MD, Dr. Sci. (Med.), Associate Professor
Russian Federation, MakhachkalaMilana M. Gadzhimuradova
Dagestan State Medical Academy
Email: xakerov72@mail.ru
ORCID iD: 0000-0002-5119-5210
SPIN-code: 9376-8335
Russian Federation, Makhachkala
Irina E. Torshina
Smolensk State Medical University
Email: irina-torsina@mail.ru
ORCID iD: 0000-0002-6562-0556
SPIN-code: 1222-6560
MD, Dr. Sci. (Med.), Associate Professor
Russian Federation, SmolenskMagomed G. Magomedov
Dagestan State Medical Academy
Email: magomedov_1957@mail.ru
ORCID iD: 0000-0003-1897-6784
SPIN-code: 1798-0529
MD, Dr. Sci. (Med.), Professor
Russian Federation, MakhachkalaMadina G. Alieva
Republican Skin and Venereological Dispensary
Email: madiina444@yandex.ru
ORCID iD: 0000-0001-7718-1610
SPIN-code: 3293-6775
Russian Federation, Makhachkala
References
- Itin P, Salgado DA. [Important genodermatoses for the practitioner. (In German).] Hautarzt. 2013;64(1):26–31. doi: 10.1007/s00105-012-2409-9
- Kern JS, Grüninger G, Imsak R, et al. Forty-two novel COL7A1 mutations and the role of a frequent single nucleotide polymorphism in the MMP1 promoter in modulation of disease severity in a large European dystrophic epidermolysis bullosa cohort. Br J Dermatol. 2009;161(5):1089–1097. doi: 10.1111/j.1365-2133.2009.09333.x
- Chamcheu JC, Siddiqui IA, Syed DN, et al. Keratin gene mutations in disorders of human skin and its appendages. Arch Biochem Biophys. 2011;508(2):123–137. doi: 10.1016/j.abb.2010.12.019
- Bulić SO, Kotrulja L, Sjerobabski-Masnec I. [Wounds and dermatoses. (In Croatian).] Acta Med Croatica. 2012;66(1):29–35.
- Danial C, Adeduntan R, Gorell ES, et al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol. 2015;32(1):53–59. doi: 10.1111/pde.12391
- Prodinger C, Bauer JW, Laimer M. Translational perspectives to treat epidermolysis bullosa-where do we stand? Exp Dermatol. 2020;29(11):1112–1122. doi: 10.1111/exd.14194
- Meyer O. Testing and assessment strategies, including alternative and new approaches. Toxicol Lett. 2003;(140-141):21–30. doi: 10.1016/s0378-4274(02)00492-7
- Claudio L, Kwa WC, Russell AL, Wallinga D. Testing methods for developmental neurotoxicity of environmental chemicals. Toxicol Appl Pharmacol. 2000;164(1):1–14. doi: 10.1006/taap.2000.8890
- Bal-Price AK, Hogberg HT, Buzanska L, Coecke S. Relevance of in vitro neurotoxicity testing for regulatory requirements: Challenges to be considered. Neurotoxicol Teratol. 2010;32(1):36–41. doi: 10.1016/j.ntt.2008.12.003
- Magnol JP, Pin D, Palazzi X, et al. [Characterization of a canine model of dystrophic bullous epidermolysis (DBE). Development of a gene therapy protocol. (In French).] Bull Acad Natl Med. 2005;189(1):107–119.
- Terada Y, Nagata M, Murayama N, et al. Clinical comparison of human and canine atopic dermatitis using human diagnostic criteria (Japanese Dermatological Association, 2009): Proposal of provisional diagnostic criteria for canine atopic dermatitis. J Dermatol. 2011;38(8):784–790. doi: 10.1111/j.1346-8138.2010.01136.x
- Marsella R, Olivry T, Carlotti DN. International task force on canine atopic dermatitis. current evidence of skin barrier dysfunction in human and canine atopic dermatitis. Vet Dermatol. 2011;22(3):239–248. doi: 10.1111/j.1365-3164.2011.00967.x
- Schön MP, Manzke V, Erpenbeck L. Animal models of psoriasis-highlights and drawbacks. J Allergy Clin Immunol. 2021;147(2):439–455. doi: 10.1016/j.jaci.2020.04.034
- Boehncke WH. [Psoriasis in the animal model. (In German).] Hautarzt. 1997;48(10):707–713. doi: 10.1007/s001050050648
- Zhang Y, Gilliam AC. Animal models for scleroderma: An update. Curr Rheumatol Rep. 2002;4(2):150–162. doi: 10.1007/s11926-002-0011-3
- Neagu M, Caruntu C, Constantin C, et al. Chemically induced skin carcinogenesis: Updates in experimental models (Review). Oncol Rep. 2016;35(5):2516–2528. doi: 10.3892/or.2016.4683
- Hofstetter J, Suckow MA, Hickman DL. Morphophysiology. Chapter 4 in book: The laboratory rat. Ed. by M.A. Suckow, S.H. Weisbroth, C.L. Franklin. Elsevier Academic Press, USA; 2006. 929 р.
- Gushchin YA, Kovaleva MA. Comparative morphology of human and laboratory animals. Laboratory Animals for Science. 2019;(2):6. EDN: GNZOWC doi: 10.29296/2618723X-2019-02-06
- Parker GA, Picut CA. Atlas of histology of the juvenile rat. Academic Press; 2016. 462 р.
- Plikus MV, Chuong CM. Complex hair cycle domain patterns and regenerative hair waves in living rodents. J Investigat. Dermatol. 2008;(128):1071–1080.
- Stricker-Krongrad A, Shoemake CR, Liu J, et al. The importance of minipigs in dermal safety assessment: An overview. Cutan Ocul Toxicol. 2016;(10):1–9. doi: 0.1080/15569527.2016.1178277
- Treuting PM, Dintzis SM, Frevert CW, et al. Comparative anatomy and histology: A mouse and human atlas. Elsevier; 2012. 461 р.
- Makarov VG, Makarova MN, Abrashova TV, et al. Physiological, biochemical and biometric indices of norm of experimental animals. Reference book. Saint Petersburg: LEMA; 2013. 116 р. (In Russ).
- Lucky AW, Whalen J, Rowe S, et al. Diagnosis and care of the newborn with epidermolysis bullosa. Neoreviews. 2021;22(7):e438–e451. doi: 10.1542/neo.22-7-e438
- Pope E, Lara-Corrales I, Mellerio JE, et al. Epidermolysis bullosa and chronic wounds: A model for wound bed preparation of fragile skin. Adv Skin Wound Care. 2013;26(4):177–188; quiz 189-190. doi: 10.1097/01.ASW.0000428864.72412.b7
- Stalder JF, Tennstedt D, Deleuran M, et al. Fragility of epidermis and its consequence in dermatology. J Eur Acad Dermatol Venereol. 2014;28(l4):1–18. doi: 10.1111/jdv.12509
- Epstein EH. Molecular genetics of epidermolysis bullosa. Science. 1992;256(5058):799–804. doi: 10.1126/science.1375393
- Lynne V, Burns L, Handsaker J, Murdoch JM. Epidermolysis bullosa: Management complexities for paediatric patients. J Nurs. 2018;27(12):S20–S25. doi: 10.12968/bjon.2018.27.Sup12.S20